

Additional reading on safety, education and challenges associated with oncology care:

Neuss MN, Gilmore TR, Belderson KM, et al. 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards, Including Standard for Pediatric Oncology. *ONF*, 44(1), A1-A13. Doi: 10.1200/JOP.2016.017905

Galassi A, Morgan C, Muha C. Making the invisible visible: Oncology nursing efforts of NCI-designated cancer centers in LMICs. *Journal of Cancer Policy*. 2017 <https://doi.org/10.1016/j.jcpo.2017.03.013>

Wyatt TE, Pernenkel V, Akinyemiju TF. *Preventive Medicine Reports*. <https://doi.org/10.1016/j.pmedr.2017.04.001>

Additional reading for patients with comorbidities:

Von Moos R, Costa L, Ripamonti CI, Nepal D, Santini D. Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain. *European Journal of Cancer*. Vol 71, pp 80-94. <https://doi.org/10.1016/j.ejca.2016.10.021>

Ugalde A, Haynes K, Boltong A, White V, Krishasamy M. Self-guided interventions for managing psychological distress in people with cancer – A systematic review. *Patient Education and Counseling*. Vol 100, Iss 5, pps 846-857. <https://doi.org/10.1016/j.pec.2016.12.009>

Strong V, Waters R, Hibberd C, Murray G, Wall L, et al. Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. *The Lancet*. 2008 Vol 372, Iss 9632, 5-11, pgs 40-48.

Paice JA, Mulvey M, Bennett M, Dougherty PM, et al. AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions. *The Journal of Pain*. Vol 18, No 3. Pp 233-246. <http://dx.doi.org/10.1016/j.jpain.2016.10.020>

Sogaard M, Wernich Thomsen R, Skovgaard K, et al. The impact of comorbidity on cancer survival: a review. *Clinical Epidemiology*. 2013;5(Suppl 1):3-29. Doi: 10.2147/CLEP.S47150

Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. *CA Cancer J Clin*. 2016; 66:337-350. Doi: 10.3322/caac.27342

Edwards BK, Noone AM, Marlotto AB, et al. Annual Report to the Nation on the Status of Cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast or prostate cancer. 2014. 120: 1290-1314. Doi: 10.1002/cncr.28509

Additional reading for patients of older age:

Colussi AM, Mazzer L, Candotto D, De Biasi M, De Lorenzi L, Pin I, Pusiol N, Romanin, C, Zamattio V. The elderly cancer patient: a nursing perspective. *Critical Reviews in Oncology/Hematology* 39 (2001) 235-245. Available here

Van Abbema D, van Vuuren A, van den Berkmortel F, et al. Functional status decline in older patients with breast and colorectal cancer after cancer treatment: A prospective cohort study. *Journal of Geriatric Oncology*. 8, pps 176-184. <http://dx.doi.org/10.1016/j.jgo.2017.01.003>

Van Deudekom FJ, Schimberg AS, et al. Functional and cognitive impairment, social environment, frailty and adverse health outcomes in older patients with head and neck cancer, a systematic review. Oral Oncology. 2017. Vol 64, Pp 27-36. <https://doi.org/10.101/j.oraloncology.2016.11.013>

Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol. 2015; 26(2):288-300. <https://doi.org/10.1093/annonc/mdu210>

Pallis AG, Gridelli C, Wedding U. Management of elderly patients with NSCLC: updated expert opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Ann Onc. 2014; 25(7)1270-1283. <https://doi.org/10.1093/annonc/mdu022>

Exterman M. Geriatric Oncology: An Overview of Progress and Challenges. Cancer Res Treat. 2010; 42(2) 61-68.

Additional Resources for patient centered material:

American Cancer Society. Site available at: <https://www.cancer.org/>

OncoLink Site Available at: <https://www.oncolink.org/>

NCCN Guidelines for Patients. Available at: <https://www.nccn.org/patients/guidelines/cancers.aspx>

CancerCare. Available at: <http://www.cancercare.org/>

Additional Reading:

Abdel-Rahman O. Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. *Crit Rev Oncol Hematol*. 2016;101:75-85.

Abdel-Rahman O, ElHalawani H, Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. *Future Oncol*. 2015;11(17):2471-2484.

Bellmunt J, Mullane SA, Werner L, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. *Ann Oncol*. 2015;26:812-817.

Borrello IM, Schaffer MM, Roehrl E, et al. Identification of differences in immunotherapy knowledge and practice patterns among oncologists from six European countries. *Mol Clin Oncol*. 2014;2:269–74.

Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin based chemotherapy in patients with urothelial carcinoma of the bladder. *Cancer*. 2006;107:506-513.

De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II—results of EORTC study 30986. *J Clin Oncol*. 2009;27:5634-5639.

Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. *Annu Rev Immunol*. 2004;22:329-60.

Fehrenbacher L, Spira A, Ballinger M, et al. POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. *Lancet*. 2016;387(10030):1837-46.

Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359-86.

Garon EB. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. *Semin Oncol*. 2015;42(Suppl 2):S11-S18.

Gettinger Sn, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, et al. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2016;34(25):2980-7.

Herbst R, Baas P, Kim D, Felip E, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* 2016; 387: 1540–50.

Herbst RS, Heymach JV, Lippman SM. Lung Cancer. *N Engl J Med*. 2008;359:1367-1380.

Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*. 2010;363(8):711-723.

Ilie M, Long-Mira E, Bence C, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. *Ann Oncol*. 2016;27(1):147-153.

Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. *J Leukoc Biol.* 2013;94(1):25-39.

Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. *Lancet.* 2009;374:239-249.

Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). *Ann Oncol.* 2016;27(8):1492-504.

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer.* 2012;12(4):252-64.

Pennell NA. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer. *Semin Oncol.* 2015 Oct;42(Suppl 2):S3-S10.

Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med.* 2011;364:2517-2526.

Rouprêt M, Babjuk M, Böhle A, et al. European Association of Urology 2015. Guidelines on

Taube J, Anders R, Young G, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. *Sci Transl Med.* 2012;4(127):127-137.

Topalian SL, Hodi FS, Brahmer JR, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. *N Engl J Med.* 2012;366(26):2443-54.